The Immune Response Corporation (Nasdaq:IMNR) today announced the appointment of Paul Volberding, M.D. to its Scientific Advisory Board. Dr. Volberding, one of the foremost experts on HIV/AIDS, is professor and vice chair of the Department of Medicine at the University of California, San Francisco (UCSF) and principal investigator and co-director of UCSF's Center for AIDS Research. He also is chief of Medical Service at the San Francisco VA Medical Center.

"I am very pleased to announce the appointment Dr. Volberding to the Immune Response Corporation's Scientific Advisory Board," said John N. Bonfiglio, Ph.D., the company's chief executive officer. "Dr. Volberding brings world-class expertise in HIV/AIDS clinical research and development to the company as we push for the commercialization of REMUNE(R), our immune-based therapeutic vaccine candidate. I look forward to working with Dr. Volberding and the other members of our newly-formed Scientific Advisory Board in this endeavor."

Dr. Volberding is a founding member and chair of the Board of Directors of the International AIDS Society-USA. He has served on numerous national committees over the course of his career including the National Academy of Sciences (Institute of Medicine) AIDS Policy Review Steering Committee, National Institutes of Health AIDS Drug Selection Committee, National Institute of Allergy and Infectious Disease, Institute of Medicine Round Table and the AIDS Clinical Trials Group Executive Committee.

Dr. Volberding co-founded one of the first AIDS-designated clinics in the early 1980s at San Francisco General Hospital, where he established a model program of AIDS patient care, research and professional education. In 1990, he co-chaired the Sixth International Conference on AIDS and has served on the International Advisory Committees for all subsequent International Conferences.

Dr. Volberding's primary research focus is the clinical trial of antiretroviral drugs. He has been instrumental in testing many compounds, but is best known for groundbreaking trials establishing standards of care for the use of zidovudine in asymptomatic HIV infection.

He is co-editor in chief of the Journal of Acquired Immune Deficiency Syndrome and co-editor of The Medical Management of AIDS, the most widely used textbook of HIV medicine, now in its sixth edition.

Dr. Volberding earned his undergraduate and medical degrees at the University of Chicago and the University of Minnesota respectively. He finished his training at the University of Utah and UCSF, where he studied for two years as a research fellow in the virology laboratory of Jay Levy, M.D., who went on to co-discover HIV/AIDS.

Other members of The Immune Response Corporation's Scientific Advisory Board include: Chairman Gilbert S. Omenn, M.D., Ph.D., professor of Internal Medicine, Human Genetics and Public Health, University of Michigan; Mario Salvatore Clerici, M.D., chair of Immunology, University of Milan; B.G. Gazzard, M.A., M.D., F.R.C.P., professor, Chelsea & Westminster Hospital in London; Eduardo Fernandez-Cruz, M.D., professor and head of the Department of Immunology, University General Hospital Gregorio Maranon in Madrid and principal investigator of the 2102 clinical trial of REMUNE(R) in Spain.

About The Immune Response Corporation and REMUNE(R)

Co-founded by medical pioneer Dr. Jonas Salk and headquartered in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company dedicated to treating HIV and AIDS through the development of REMUNE(R). REMUNE(R) is an immune-based therapeutic vaccine designed to induce an HIV-specific immune response and boost the body's natural defense mechanisms in order to slow the virus' progression. REMUNE(R) is comprised of HIV that has been chemically killed and inactivated so that it is non-infectious. During the inactivation process, the HIV outer envelope, which is prone to rapid mutations, is removed. REMUNE(R) is then emulsified in Incomplete Freund's Adjuvant, an agent that elicits a more potent immune response by drawing the immune system's attention to the inactivated virus.

HIV, the human immunodeficiency virus, is the virus that causes AIDS, a condition that slowly destroys the body's immune system, making it vulnerable to infections. More than 60 million people have been infected with HIV since it was first recognized in 1981. Today, 40 million people around the world are living with HIV.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE(R), the uncertainty of successful completion of any such clinical trials, whether REMUNE(R) will be effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE(R) in preclinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2002, and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation.

Return to Omenn syndrome

Home

Contact

Resources

Exchange Links

ebay